Dianthus Therapeutics To Participate in the 8th Annual Evercore Healthcare Conference
Dianthus Therapeutics (NASDAQ:DNTH) had its price target raised by analysts at HC Wainwright from $40.00 to $47.00. They now have a "buy" rating on the stock.
Assessing Dianthus Therapeutics (DNTH) Valuation Following Strong Revenue Growth and Recent Share Price Momentum [Yahoo! Finance]
Dianthus Therapeutics (NASDAQ:DNTH) had its price target raised by analysts at Wedbush from $44.00 to $46.00. They now have an "outperform" rating on the stock.
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results